SCHEMBL4518988

SCHEMBL4518988

CC(C)C(NCC(C)(C)N)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 6/20 0.51
CYP3A4 P08684 2/20 0.51
MAP1LC3B Q9GZQ8 1/20 0.51
CYP2C19 P33261 1/20 0.51
KCNH2 Q12809 1/20 0.51
TDP1 Q9NUW8 1/20 0.46
EGFR P00533 1/20 0.44
MAPK8 P45983 1/20 0.41
MAPK9 P45984 1/20 0.41
PTGS1 P23219 1/20 0.41
PTGS2 P35354 1/20 0.41
POLB P06746 1/20 0.41
RAB9A P51151 1/20 0.41
ALOX5AP P20292 1/20 0.41
PDE1C Q14123 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4513091 0.84 KIF11 (0.48) KIF11CYP3A4MAP1LC3BCYP2C19KCNH2
SCHEMBL4522589 0.84 KIF11 (0.48) KIF11CYP3A4MAP1LC3BCYP2C19KCNH2
SCHEMBL5724300 0.83 KIF11 (0.55) KIF11CYP3A4MAP1LC3BCYP2C19KCNH2
SCHEMBL5517277 0.82 KIF11 (0.49) KIF11CYP3A4MAP1LC3BCYP2C19KCNH2
SCHEMBL5523051 0.82 KIF11 (0.49) KIF11CYP3A4MAP1LC3BCYP2C19KCNH2
SCHEMBL5648475 0.81 KIF11 (0.50) KIF11CYP3A4MAP1LC3BCYP2C19KCNH2
SCHEMBL5649327 0.81 KIF11 (0.50) KIF11CYP3A4MAP1LC3BCYP2C19KCNH2
SCHEMBL5646819 0.81 KIF11 (0.50) KIF11CYP3A4MAP1LC3BCYP2C19KCNH2
SCHEMBL4519529 0.81 KIF11 (0.56) KIF11CYP3A4MAP1LC3BCYP2C19KCNH2
SCHEMBL4283747 0.81 KIF11 (0.56) KIF11CYP3A4MAP1LC3BCYP2C19KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7528137-B2 Compounds, compositions, and methods CYTOKINETICS, INC. (US) 2009-05-05 US disclosed
US-7214800-B2 Compounds, compositions, and methods CYTOKINETICS, INC. (US) 2007-05-08 US disclosed
EP-1553931-A4 COMPOUNDS, COMPOSITIONS, AND METHODS CYTOKINETICS INC (US) 2006-08-30 EP disclosed
US-20060094735-A1 Compounds, compositions, and methods CYTOKINETICS, INC. 2006-05-04 US disclosed
EP-1553931-A1 COMPOUNDS, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2005-07-20 EP disclosed
US-20040077668-A1 Compounds, compositins, and methods CYTOKINETICS, INC. 2004-04-22 US disclosed
WO-2003097053-A1 COMPOUNDS, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077668-A1 Compounds, compositins, and methods CEP170, PSAP, PACSIN2 KIF11 1233/4885CYP3A4 4624/4885MAP1LC3B 1225/4885
US-20060094735-A1 Compounds, compositions, and methods ALPP, PCNA, MKI67 KIF11 562/4885CYP3A4 4722/4885MAP1LC3B 1330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.